Overactive bladder symptoms Genitourinary syndrome of menopause Urinary microbiome dysbiosis Urinary metabolomic alterations in breast cancer survivors on aromatase inhibitors Overactive Bladder Urinary Microbiome Metabolomics Breast Cancer Survivors Aromatase Inhibitors Genitourinary Syndrome of Menopause Lower Urinary Tract Symptoms Urine Metabolome Microbial Dysbiosis Precision Medicine
Conditions
Interventions
Postmenopausal breast cancer survivors aged 50 to 65 years receiving letrozole or anastrozole for more than 6 months who meet symptom based overactive bladder criteria using Overactive Bladder Symptom
Basic Science,Basic Science
OAB,Non OAB
Sponsors
International Urogynecological Association
Eligibility
Sex/Gender
Female
Age
50 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Female sex 2. Age 50 to 65 years 3. Postmenopausal status defined as amenorrhea for at least 12 months without prior hysterectomy 4. History of breast cancer 5. Receiving letrozole or anastrozole for more than 6 months 6. Able and willing to provide written informed consent
Exclusion criteria
Exclusion criteria: 1. Abnormal vaginal bleeding 2. History of menopausal hormone therapy 3. Antibiotic use within the past 30 days 4. Urinary catheterization or bladder or urethral procedures within the past 30 days 5. Current urinary tract infection or infection within the past 4 weeks 6. Treatment or medication for urinary symptoms within the past 30 days 7. Pelvic organ prolapse stage 2 or higher 8. Neurological disorders affecting bladder function 9. Diabetic cystopathy or bladder outlet obstruction 10. Use of medications affecting bladder activity 11. History of bladder or pelvic malignancy or pelvic radiation 12. Prior pelvic surgery affecting bladder function 13. Severe cognitive impairment or psychiatric illness 14. Uncontrolled systemic disease 15. Incomplete data or refusal to participate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Urinary microbiome composition Single visit baseline at enrollment 16S rRNA gene sequencing of midstream urine with comparison of relative abundance and diversity between OAB and non OAB groups | — |
Secondary
| Measure | Time frame |
|---|---|
| Urinary metabolome profile Single visit baseline at enrollment Liquid chromatography mass spectrometry analysis of midstream urine to compare metabolite features and pathway profiles between OAB and non OAB groups | — |
Countries
Thailand
Contacts
Public ContactApisith Saraluck
Faculty of Medicine Ramathibodi Hospital, Mahidol University
Outcome results
None listed